Measurement of women's breast cancer risk
Breast cancer screening adjusted to each woman's risk seems attractive for many reasons, but an important prerequisite is - of course - that the risk measurement is valid. That is what we set out to test in the recent publication in British Journal of Cancer.
cfDNA dynamics decipher mechanism of action of Ibrutinib in patients with MCL
We investigated cfDNA dynamics prior to and during induction treatment of patients with MCL treated within the TRIANGLE trial and showed an early and superior disease clearance when treated with Ibrutinib and hints toward improved disease clearance in lymph nodes than using chemotherapy
The architectonics of cancer tissue: a “bulk” analytical framework to study cancer tissue organization
Solid tumors are diagnosed by histopathology, which recognizes abnormal tissue architecture. We asked whether these changes are random or follow recurring rules. Using large-scale bulk RNA-seq, we derived quantitative “architecture” signatures that stratify cancers and link to prognosis.
Real-time disease monitoring predicts early relapse and refines conventional imaging in patients with DLBCL
Monitoring lymphoma treatment has long relied on PET-CT scans, but these are imperfect. Circulating tumor DNA (ctDNA) offers a minimally invasive, highly specific way to track disease in real time. In our study, we explored how ctDNA can reshape response assessment in DLBCL.
DARPP‑32 Beyond the Brain: A Potential Regulator of Macrophage M2 Polarization Through STAT6 Signalling
DARPP-32 orchestrates macrophage polarization towards M2 subtype via JAK1/STAT6/SHP-1 axis, fostering an immunosuppressive tumor microenvironment supporting tumor growth.
Challenges in Second-Line Therapy for Advanced Pancreatic Cancer: The Search for Predictive Markers
Patients with advanced pancreatic cancer face poor outcomes. After first-line therapy failure, only ~50% receive second-line treatment. Choosing this therapy is challenging due to the lack of reliable predictive markers for its effectiveness
Unlocking the Role of Long Non-Coding RNAs in Multiple Myeloma: The LINC01432–CELF2 Axis
By combining clinical genomics with RNA biology, we uncovered a new mechanism through which a long non-coding RNA helps myeloma cells evade apoptosis, while training the next generation of scientists to make new discoveries.
From Orphan Receptor to Metastatic Catalyst: Unveiling the Role of GPR107 in Breast Cancer Progression
GPR107 orchestrates breast cancer metastasis through a β-arrestin/ERK/STAT3 signaling axis that coordinately dismantles the collagen IV barrier via enhanced degradation, Clathrin-mediated endocytosis, and transcriptional suppression.
When Silence Speaks: How BRCA1 Hypermethylation Fuels Sporadic Breast Cancers
Targeted promoter hypermethylation of BRCA1 uncovers how epigenetic silencing integrates transcriptional repression, hormonal adaptation, and immune modulation to reshape tumor identity.
